Capstone Therapeutics Announces Completion of Enrollment for First of Two AZX100 Phase 2 Pilot Studies in Keloid Scarring

July 14, 2009 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

TEMPE, Ariz., July 14, 2009 (GLOBE NEWSWIRE) -- Capstone Therapeutics (Nasdaq:CAPS) announced today the completion of enrollment for the first of its two ongoing AZX100 Phase 2 pilot clinical trials in keloid scarring.

Twitter
LinkedIn
Facebook
Email
Print

Clinical research Phase 2